Zai Lab

Zai Lab Stock-Based Compensation

The Stock-Based Compensation (SBC) of Zai Lab (ZLAB) as of Nov 22, 2026 is 65.60 M USD. In the previous year, Stock-Based Compensation (SBC) was 70.65 M USD — a change of -7.15% (lower).

Stock-Based Compensation

65.60 MUSD

YoY

-7.15%

Last updated:

Stock-Based Compensation (SBC) of Zai Lab is 2025 65.60 M USD. Stock-Based Compensation (SBC) of Zai Lab was 2024 70.65 M USD. It decreases by -7.15% lower compared to the previous year.

The Zai Lab Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2018
12.23 M USD
Jan 1, 2019
20.29 M USD
Jan 1, 2020
24.83 M USD
Jan 1, 2021
40.71 M USD
Jan 1, 2022
61.30 M USD
Jan 1, 2023
79.63 M USD
Jan 1, 2024
70.65 M USD
Jan 1, 2025
65.60 M USD
The Zai Lab Stock-Based Compensation history
YEARStock-Based CompensationYoY
65.60 MUSD-7.15%
70.65 MUSD-11.28%
79.63 MUSD+29.90%
61.30 MUSD+50.57%
40.71 MUSD+63.97%
24.83 MUSD+22.37%
20.29 MUSD+65.92%
12.23 MUSD+23.14%
9.93 MUSD+101.64%
4.93 MUSD+82.32%
2.70 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Zai Lab Stock analysis

What does Zai Lab do? Zai Lab Ltd, based in Pudong, China, is a biopharmaceutical company operating in the Health Care sector. It develops and commercializes innovative treatments for oncology, immunology, neuroscience, and infectious diseases. The company offers products such as Zejula for ovarian cancer, VYVGART for myasthenia gravis, NUZYRA for bacterial infections, Optune for brain tumors, Qinlock for gastrointestinal tumors, Xacduro for bacterial pneumonia, and Augtyro for lung cancer. Zai Lab collaborates with leading pharmaceutical firms including Pfizer and Amgen. Zai Lab is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Zai Lab stock

Stock-Based Compensation (SBC) of Zai Lab is 65.60 M USD in 2025.

Stock-Based Compensation (SBC) of Zai Lab changed from 70.65 M USD to 65.60 M USD, representing a -7.15% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) Zai Lab since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s Zai Lab historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Zai Lab

All Key Metrics — Zai Lab